
[Federal Register Volume 82, Number 81 (Friday, April 28, 2017)]
[Notices]
[Pages 19738-19739]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08596]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-1393]


Government-Owned Inventions; Availability for Licensing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed in this document is owned by an agency of 
the U.S. Government and is available for licensing to achieve 
expeditious commercialization of results of federally funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed in this document may be obtained by 
writing to the indicated licensing contact at the Food and Drug 
Administration (FDA) Technology Transfer Program, 10903 New Hampshire 
Ave., Bldg. 1, Rm. 4213, Silver Spring, MD 20993, telephone: 240-402-
2561, FAX: 301-847-3539. A signed Confidential Disclosure Agreement 
will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.
    Title of Abstract: Solid-Phase Purification of Synthetic DNA 
Sequences.
    Description of Technology: Scientists at FDA have developed a high-
throughput method for purifying full-length phosphorothioate and native 
DNA sequences. This method comprises a modified silica gel that enables 
capture of DNA sequences functionalized with a novel linker 
specifically designed for exclusive capture of full-length sequences. 
This

[[Page 19739]]

technology has been shown to generate DNA sequences of high purity 
without the need of expensive equipment and associated accessories. 
This discovery may improve the availability of pure DNA sequences for 
clinical and/or synthetic biology applications.
    Potential Commercial Applications:
     A high-throughput purification technique for producing 
small and large quantities of highly pure DNA sequences.
    Competitive Advantages:
     Cost effective.
     High-throughput capabilities.
     Time saving.
     High purity.
    Development Stage:
     In vitro data available.
    Inventors:
    Serge L. Beaucage.
    Andrzej Grajkowski.
    Publication: Grajkowski, A., J. Cieslak, and S.L. Beaucage, 
``Solid-Phase Purification of Synthetic DNA Sequences,'' The Journal of 
Organic Chemistry, 81 (15): pp. 6165-6175, 2016; DOI: 10.1021/
acs.joc.6b01020.
    Intellectual Property: U.S. Provisional Patent Application No. 62/
356,214, filed June 29, 2016, FDA Reference No. E-2016-005.
    Licensing and Collaborative Research Opportunity:
    Parties interested in licensing this technology should contact 
Charlene Maddox at Charlene.Maddox@fda.hhs.gov or 
FDAInventionlicensing@fda.hhs.gov.

    Dated: April 19, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-08596 Filed 4-27-17; 8:45 am]
 BILLING CODE 4164-01-P


